This is a revision of a competitive renewal of an existing funded project to identify prostate cancer (PCa) risk enhancers and their target genes. We intend to identify all target genes affected by newly identified enhancers that contain genetic variation at 77 known PCa risk loci. The major `problem' of genome-wide association (GWAS) loci is the lack of mechanistic understanding of how risk alleles function. This is exacerbated by the fact that the vast majority (>90% of PCa risk alleles) resides in non-coding DNA such as enhancers. This application therefore intends to systematically identify target genes of all the newly identified PCa risk enhancers using three independent approaches, formulated here as three specific aims under the auspices of three co-PIs. The three aims are: eQTL (Coetzee) to link SNP genotypes with levels of gene expression genome-wide, CRISPRs (Farnham) to edit enhancers in situ (deletion and allelic replacement) linking them with gene expression and finally 4C (Lu) to match enhancers with potential target genes by chromatin conformation capture. The strength of this plan is that common target genes identified by all three approaches are likely to be functionally significant. Results will elucidate previously unanticipated risk mechanisms and will provide rationale for diagnosis and prevention.

Public Health Relevance

Over the last few years genetic studies have found hundreds of common genetic variations in the population that affect a person's risk of a multitude of different diseases including heart disease, diabetes and cancer. In the present project we intend to build on work done in the previous grant cycle to identify genes involved in prostate cancer risk. We hope that the data to be acquired will inform preventive and clinical benefits to individuals at risk.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA136924-08
Application #
9198754
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Fingerman, Ian M
Project Start
2008-12-01
Project End
2020-01-31
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
8
Fiscal Year
2017
Total Cost
$501,100
Indirect Cost
$196,105
Name
University of Southern California
Department
Urology
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90032
Amos, Christopher I; Dennis, Joe; Wang, Zhaoming et al. (2017) The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev 26:126-135
Kar, Siddhartha P; Adler, Emily; Tyrer, Jonathan et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer 116:524-535
Luo, Zhifei; Rhie, Suhn Kyong; Lay, Fides D et al. (2017) A Prostate Cancer Risk Element Functions as a Repressive Loop that Regulates HOXA13. Cell Rep 21:1411-1417
Cai, Mingyang; Kim, Sewoon; Wang, Kai et al. (2016) 4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locus. Sci Rep 6:22462
Lawrenson, Kate (see original citation for additional authors) (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Han, Ying; Rand, Kristin A; Hazelett, Dennis J et al. (2016) Prostate Cancer Susceptibility in Men of African Ancestry at 8q24. J Natl Cancer Inst 108:
Hazelett, Dennis J; Conti, David V; Han, Ying et al. (2016) Reducing GWAS Complexity. Cell Cycle 15:22-4
Ong, Jue-Sheng; Cuellar-Partida, Gabriel; Lu, Yi et al. (2016) Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol 45:1619-1630
Cai, Mingyang; Gao, Fan; Lu, Wange et al. (2016) w4CSeq: software and web application to analyze 4C-seq data. Bioinformatics 32:3333-3335
Hampras, Shalaka S; Sucheston-Campbell, Lara E; Cannioto, Rikki et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget 7:69097-69110

Showing the most recent 10 out of 52 publications